title: [Treatment of dyslipidemia in 2014: European versus American guidelines].
abstract: The recent American guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults have confused the debate in comparison with the European guidelines. These US guidelines prefer the notion of intensity of reduction of blood cholesterol based on the level of cardiovascular risk rather than a LDL cholesterol level target recommended by the European guidelines. Moreover, only the use of statins is recommended without any consideration for alternative pharmacological approaches in special situations. Even if we can find some similarities between these two guidelines, it is of interest to compare them carefully in order to justify the reasons why preference should be given to European guidelines.
authors.forename: Régis P
authors.initials: RP
authors.lastname: Radermecker
mesh_terms: D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood*; D050171:Dyslipidemias / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy*; D005060:Europe; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D014481:United States
chemical_list: D015415:Biomarkers; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D002784:Cholesterol